A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.

• Status: RECRUITING
• Trial end date: 2029-03-23

Summary

The purpose of eVOLVE-Lung02 is to test the effectiveness (efficacy) and measure the safety of volrustomig in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy as 1L treatment in participants with mNSCLC in PD-L1 \< 50%.

• Phase: PHASE3

Details

• Lead Sponsor: AstraZeneca
• Treatments: Carboplatin; Paclitaxel; pembrolizumab; Pemetrexed